{"id":"https://openalex.org/W4406964258","doi":null,"title":"Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.","display_name":"Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.","publication_year":2024,"publication_date":"2024-12-23","ids":{"openalex":"https://openalex.org/W4406964258","pmid":"https://pubmed.ncbi.nlm.nih.gov/39765237","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11737811"},"language":"en","primary_location":{"id":"pmh:oai:pubmedcentral.nih.gov:11737811","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11737811","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11737811/pdf/tam-32-579.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Top Antivir Med","raw_type":"Text"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11737811/pdf/tam-32-579.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053862280","display_name":"Teressa Sumy Thomas","orcid":"https://orcid.org/0000-0003-1803-8392","observed_orcids":["https://orcid.org/0000-0003-1803-8392"]},"institutions":[{"id":"https://openalex.org/I192619145","display_name":"University of the Witwatersrand","ror":"https://ror.org/03rp50x72","country_code":"ZA","type":"education","lineage":["https://openalex.org/I192619145"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Teressa S Thomas","raw_affiliation_strings":["University of the Witwatersrand, Johannesburg, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of the Witwatersrand, Johannesburg, South Africa","institution_ids":["https://openalex.org/I192619145"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5020726029","display_name":"Suman Srinivasa","orcid":"https://orcid.org/0000-0003-1950-4770","observed_orcids":["https://orcid.org/0000-0003-1950-4770"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suman Srinivasa","raw_affiliation_strings":["Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210087915"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3004,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.47820132,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"32","issue":"5","first_page":"579","last_page":"588"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.006099999882280827,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.972000002861023},{"id":"https://openalex.org/keywords/hiv","display_name":"HIV","score":0.9390000104904175},{"id":"https://openalex.org/keywords/weight-gain","display_name":"weight gain","score":0.7289999723434448},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.8920000195503235},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.8029999732971191},{"id":"https://openalex.org/keywords/cardiometabolic-risk","display_name":"cardiometabolic risk","score":0.9950000047683716},{"id":"https://openalex.org/keywords/dolutegravir","display_name":"dolutegravir","score":0.8880000114440918},{"id":"https://openalex.org/keywords/tenofovir-alafenamide","display_name":"tenofovir alafenamide","score":0.9599999785423279},{"id":"https://openalex.org/keywords/tenofovir-disoproxil-fumarate","display_name":"tenofovir disoproxil fumarate","score":0.9459999799728394},{"id":"https://openalex.org/keywords/efavirenz","display_name":"efavirenz","score":0.9950000047683716},{"id":"https://openalex.org/keywords/cardiovascular-benefits","display_name":"cardiovascular benefits","score":0.4359999895095825},{"id":"https://openalex.org/keywords/dysglycemia","display_name":"dysglycemia","score":0.6790000200271606},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.890999972820282}],"concepts":[{"id":"https://openalex.org/C14527384","wikidata":"https://www.wikidata.org/wiki/Q4693403","display_name":"Agonism","level":3,"score":0.8770893216133118},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7226866483688354},{"id":"https://openalex.org/C2778563252","wikidata":"https://www.wikidata.org/wiki/Q170617","display_name":"Glucagon","level":3,"score":0.516386091709137},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.5130819082260132},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.466748982667923},{"id":"https://openalex.org/C2776398474","wikidata":"https://www.wikidata.org/wiki/Q424611","display_name":"Glucagon-like peptide-1","level":4,"score":0.44752609729766846},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41651779413223267},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.38935720920562744},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3610886037349701},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.27836233377456665},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.14163902401924133},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.12229090929031372},{"id":"https://openalex.org/C94625758","wikidata":"https://www.wikidata.org/wiki/Q7163","display_name":"Politics","level":2,"score":0.0},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.0},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.0},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D000099226","descriptor_name":"Dolutegravir","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009765","descriptor_name":"Obesity","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015430","descriptor_name":"Weight Gain","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmh:oai:pubmedcentral.nih.gov:11737811","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11737811","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11737811/pdf/tam-32-579.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Top Antivir Med","raw_type":"Text"},{"id":"pmid:39765237","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39765237","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Topics in antiviral medicine","raw_type":"Journal Article"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:11737811","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11737811","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11737811/pdf/tam-32-579.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Top Antivir Med","raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4406964258.pdf","grobid_xml":"https://content.openalex.org/works/W4406964258.grobid-xml"},"referenced_works_count":34,"referenced_works":["https://openalex.org/W1535373147","https://openalex.org/W1951521958","https://openalex.org/W1965749245","https://openalex.org/W2258929611","https://openalex.org/W2416979112","https://openalex.org/W2519510391","https://openalex.org/W2795436691","https://openalex.org/W2922860464","https://openalex.org/W2945985905","https://openalex.org/W2979687596","https://openalex.org/W2979917028","https://openalex.org/W3036631329","https://openalex.org/W3037508799","https://openalex.org/W3127371223","https://openalex.org/W3169380571","https://openalex.org/W3194466821","https://openalex.org/W4281934192","https://openalex.org/W4296702407","https://openalex.org/W4306681944","https://openalex.org/W4319808936","https://openalex.org/W4386623174","https://openalex.org/W4386691506","https://openalex.org/W4388592674","https://openalex.org/W4388759362","https://openalex.org/W4389555309","https://openalex.org/W4389681767","https://openalex.org/W4391141493","https://openalex.org/W4391309422","https://openalex.org/W4392242245","https://openalex.org/W4393022976","https://openalex.org/W4396234476","https://openalex.org/W4399395008","https://openalex.org/W4400178611","https://openalex.org/W4400281029"],"related_works":["https://openalex.org/W7117260329","https://openalex.org/W4311753508","https://openalex.org/W7164561877","https://openalex.org/W7202162504","https://openalex.org/W7122560347","https://openalex.org/W4393022976","https://openalex.org/W4403122057","https://openalex.org/W7203823212","https://openalex.org/W4388912573","https://openalex.org/W4389030529"],"abstract_inverted_index":{"Weight":[0,76],"gain":[1,42,194],"among":[2,154,165,186,210],"persons":[3,155],"with":[4,60,99,131,156,167],"HIV":[5,73],"PWH)":[6],"on":[7],"contemporary":[8],"antiretroviral":[9],"therapy":[10],"(ART)":[11],"can":[12],"extend":[13],"beyond":[14],"an":[15],"initial":[16],"return-to-health":[17],"phenomenon":[18],"and":[19,50,57,62,71,90,135,188,198,202],"lead":[20],"to":[21,27,39,123,149,176,178,196],"overweight/obesity":[22],"in":[23,31,102,114,158],"the":[24,103,180],"first":[25],"1":[26],"2":[28],"years,":[29],"resulting":[30],"enhanced":[32],"cardiometabolic":[33,125],"risk.":[34],"Factors":[35],"that":[36],"may":[37,127],"contribute":[38],"increased":[40],"weight":[41,82,100,119,152,193],"include":[43],"specific":[44,195],"ART":[45],"regimens":[46],"(those":[47],"initiating":[48],"dolutegravir":[49],"tenofovir":[51,55],"alafenamide":[52],"or":[53],"withdrawing":[54],"disoproxil":[56],"efavirenz),":[58],"women":[59],"HIV,":[61],"certain":[63],"virologic":[64],"factors":[65],"including":[66],"lower":[67],"baseline":[68],"CD4":[69],"count":[70],"higher":[72],"viral":[74],"load.":[75],"reduction":[77,101,153],"starting":[78],"at":[79],"5%":[80],"body":[81,108],"confers":[83],"metabolic":[84,94],"protection,":[85],"such":[86],"as":[87,110],"improved":[88],"hypertension":[89],"dysglycemia.":[91],"Even":[92],"greater":[93],"impact":[95],"has":[96],"been":[97],"shown":[98,162],"approximate":[104],"range":[105],"of":[106,183],"15%":[107],"weight,":[109],"evidenced":[111],"by":[112],"decreases":[113],"cardiovascular":[115,163,169],"disease":[116],"mortality.":[117],"Effective":[118],"management":[120],"is":[121],"essential":[122],"reducing":[124],"risk,":[126],"not":[128],"be":[129],"achieved":[130],"lifestyle":[132],"changes":[133],"alone,":[134],"requires":[136],"other":[137],"therapeutic":[138],"strategies.":[139],"Glucagon-like":[140],"peptide-1":[141],"receptor":[142],"agonists":[143],"(GLP-1":[144],"RAs)":[145],"are":[146],"well":[147],"recognized":[148],"provide":[150],"potent":[151],"overweight/obesity;":[157],"addition,":[159],"studies":[160,172],"have":[161,173],"benefit":[164],"those":[166],"established":[168],"disease.":[170],"Recent":[171],"permitted":[174],"us":[175],"begin":[177],"understand":[179],"potential":[181],"role":[182],"GLP-1":[184,207],"RAs":[185],"PWH":[187,197],"overweight/obesity.":[189],"This":[190],"review":[191],"highlights":[192],"discusses":[199],"current":[200],"evidence":[201],"key":[203],"clinical":[204],"considerations":[205],"for":[206],"RA":[208],"use":[209],"PWH.":[211]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2025-01-30T00:00:00"}